RYDAPT (midostaurin) Patient Assistance Program
Don’t let the high cost of brand specialty multi-kinase inhibitor therapy disrupt your treatment. We help eligible patients access Rydapt (midostaurin) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Rydapt (midostaurin) is FDA-approved in combination with standard induction and consolidation chemotherapy for newly diagnosed FLT3-mutated acute myeloid leukemia (AML), and as a single agent for advanced systemic mastocytosis (aggressive SM, SM with associated hematological neoplasm, mast cell leukemia). It is a multi-kinase inhibitor targeting FLT3, KIT, PKC, and other kinases.
- Without assistance, Rydapt costs commonly run approximately $14,000–$18,000 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Rydapt for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Rydapt in the U.S. as of 2026. For FLT3-mutated AML, newer FLT3 inhibitors include gilteritinib (Xospata, for relapsed/refractory FLT3+ AML) and quizartinib (Vanflyta, newer, also for FLT3+ AML). Rydapt remains widely used as part of front-line FLT3+ AML therapy (with 7+3 induction).
What Is Rydapt Prescription Assistance Program?
The Rydapt Prescription Assistance Program is a manufacturer-sponsored initiative that provides Rydapt at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for FLT3-mutated AML and advanced systemic mastocytosis patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, hematology/oncology coordination, FLT3 mutation documentation, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Rydapt costs roughly $14,000–$18,000/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$17,000 | Save substantially |
| CVS Pharmacy | ~$18,000 | Save substantially |
| Walmart | ~$14,500 | Save substantially |
| Costco | ~$14,200 | Save substantially |
Specialty Pharmacy | ~$15,500 | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Rydapt Prescription Program?
The Patient Assistance Program is free to apply for and provides Rydapt at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Rydapt:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $14,000–$18,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Rydapt assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Rydapt Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Rydapt:
Rydapt (midostaurin) is an oral multi-kinase inhibitor used in combination with standard chemotherapy for newly diagnosed FLT3-mutated AML, and as a single agent for advanced systemic mastocytosis. It targets multiple kinases including FLT3 (mutant and wild-type), KIT (including the D816V mutation in mastocytosis), PKC isoforms, VEGFR, and others.
How Rydapt Works:
Activating FLT3 mutations occur in about 30% of AML patients and are associated with a poor prognosis and high relapse rates when treated with chemotherapy alone. Midostaurin works by inhibiting both wild-type and mutant FLT3, which significantly improves event-free and overall survival when added to standard induction and consolidation chemotherapy. Additionally, the drug targets KIT mutations, including the common KIT D816V driver mutation. This specialized KIT inhibition effectively reduces mast cell burden and improves overall disease control for patients with advanced systemic mastocytosis.
Form and use:
For newly diagnosed FLT3-positive AML, Rydapt is administered as a 50 mg oral dose taken twice daily with food on days 8 through 21 of each 28-day chemotherapy cycle. Following the induction and consolidation phases, it can be continued as a single-agent maintenance therapy for up to 12 cycles. For patients treating advanced systemic mastocytosis, the medication is prescribed at a higher dose of 100 mg twice daily taken continuously. Taking the medication with food, especially fatty meals, is required as it enhances the drug’s absorption.
Generic availability:
As of 2026, there is no generic version of Rydapt available in the United States. Other specialized FLT3 inhibitors on the market include gilteritinib, which is approved for relapsed or refractory FLT3-positive AML, and quizartinib, a newer therapy used alongside induction chemotherapy. For the treatment of systemic mastocytosis, avapritinib is another available option. Avapritinib is often preferred over midostaurin for many mastocytosis patients due to its superior selectivity for the KIT D816V mutation.
Warnings:
Rydapt carries serious warnings for pulmonary toxicity, such as interstitial lung disease and pneumonitis, requiring immediate discontinuation at the first sign of symptoms. It also poses risks for embryo-fetal toxicity and has significant drug interactions as a CYP3A substrate, meaning strong CYP3A inhibitors or inducers can unsafely alter its levels. Other common or notable adverse events associated with its use include severe nausea and vomiting, febrile neutropenia, mucositis, headache, hyperglycemia, QT prolongation, and elevated lipase or amylase levels.
FAQ (Frequently Asked Questions)
How Much Does Rydapt Cost Without Insurance?
Rydapt costs approximately $14,000–$18,000 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Rydapt at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Do I Need FLT3 Mutation Testing?
Rydapt’s AML approval is specifically for patients with FLT3 mutations (FLT3-ITD or FLT3-TKD). FLT3 mutation testing on tumor (bone marrow) is required before starting. About 30% of AML patients have FLT3 mutations. Without an FLT3 mutation, Rydapt is not approved for AML use — but it is approved for systemic mastocytosis regardless of FLT3 status (mastocytosis is driven by KIT mutations).
How Does Rydapt Fit Into AML Treatment?
For newly diagnosed FLT3+ AML in patients fit for intensive induction: Rydapt is added on days 8–21 of each 28-day chemo cycle during 7+3 induction and consolidation. After induction/consolidation, Rydapt continues as maintenance for up to 12 cycles. The RATIFY trial showed improved overall survival vs. chemotherapy alone. Allogeneic stem cell transplant is often considered after consolidation for high-risk FLT3+ AML.
How Is Rydapt Different From Xospata?
Both target FLT3. Rydapt (midostaurin) is a multi-kinase inhibitor (FLT3, KIT, PKC, others) used in newly diagnosed FLT3+ AML with chemotherapy. Xospata (gilteritinib) is a more selective FLT3 inhibitor used as monotherapy in relapsed/refractory FLT3+ AML. Quizartinib (Vanflyta) is another newer selective FLT3 inhibitor for FLT3-ITD AML in combination with induction. These FLT3 inhibitors target different settings in the AML treatment journey.
What About Systemic Mastocytosis?
Rydapt is FDA-approved for advanced systemic mastocytosis (aggressive SM, SM-AHN, mast cell leukemia) at 100 mg BID continuously. For mastocytosis specifically, Rydapt targets KIT D816V (the most common driver mutation). However, avapritinib (Ayvakit) — a more potent and selective KIT D816V inhibitor — is now FDA-approved for both indolent and advanced SM and is preferred over midostaurin for many SM patients in 2026.
Can I Get Rydapt Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — for AML: discussing newer FLT3 inhibitors (quizartinib) for newly diagnosed FLT3-ITD, Xospata for relapsed/refractory, or non-FLT3-targeted regimens; for SM: switching to avapritinib (Ayvakit), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Leukemia & Lymphoma Society, The Mast Cell Disease Society, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Rydapt, our team may be able to help you access assistance programs designed to make brand specialty multi-kinase inhibitor therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.